OBIO Stock Overview
Orchestra BioMed Holdings, Inc. operates as a biomedical innovation company.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Orchestra BioMed Holdings, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$4.39 |
| 52 Week High | US$20.19 |
| 52 Week Low | US$4.22 |
| Beta | 0.14 |
| 1 Month Change | -16.70% |
| 3 Month Change | -42.84% |
| 1 Year Change | -70.87% |
| 3 Year Change | -58.93% |
| 5 Year Change | n/a |
| Change since IPO | -61.49% |
Recent News & Updates
Shareholder Returns
| OBIO | US Medical Equipment | US Market | |
|---|---|---|---|
| 7D | -2.4% | 2.0% | 2.2% |
| 1Y | -70.9% | -1.4% | 22.8% |
Return vs Industry: OBIO underperformed the US Medical Equipment industry which returned -2% over the past year.
Return vs Market: OBIO underperformed the US Market which returned 22.3% over the past year.
Price Volatility
| OBIO volatility | |
|---|---|
| OBIO Average Weekly Movement | 8.9% |
| Medical Equipment Industry Average Movement | 7.3% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.5% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: OBIO's share price has been volatile over the past 3 months.
Volatility Over Time: OBIO's weekly volatility has decreased from 17% to 9% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | 56 | David Hochman | orchestrabiomed.com |
Orchestra BioMed Holdings, Inc. operates as a biomedical innovation company. The company’s flagship product candidates include BackBeat Cardiac Neuromodulation Therapy (CNT) for the treatment of hypertension (HTN); and Virtue Sirolimus AngioInfusion Balloon (SAB) for the treatment of atherosclerotic artery disease. Its products also comprise FreeHold devices and minimally invasive surgery devices.
Orchestra BioMed Holdings, Inc. Fundamentals Summary
| OBIO fundamental statistics | |
|---|---|
| Market cap | US$157.10m |
| Earnings (TTM) | -US$49.12m |
| Revenue (TTM) | US$2.76m |
56.9x
P/S Ratio-3.2x
P/E RatioIs OBIO overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| OBIO income statement (TTM) | |
|---|---|
| Revenue | US$2.76m |
| Cost of Revenue | US$186.00k |
| Gross Profit | US$2.57m |
| Other Expenses | US$51.69m |
| Earnings | -US$49.12m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.37 |
| Gross Margin | 93.26% |
| Net Profit Margin | -1,779.71% |
| Debt/Equity Ratio | 0% |
How did OBIO perform over the long term?
See historical performance and comparison